These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17502923)

  • 21. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH).
    Sazci A; Ergul E; Aygun C; Akpinar G; Senturk O; Hulagu S
    Cell Biochem Funct; 2008 Apr; 26(3):291-6. PubMed ID: 17563923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
    Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
    Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease.
    Nakamuta M; Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Yada M; Yada R; Takemoto R; Fukuizumi K; Harada N; Taketomi A; Maehara Y; Nakashima M; Enjoji M
    Int J Mol Med; 2008 Nov; 22(5):663-7. PubMed ID: 18949388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease.
    Pirola CJ; Gianotti TF; Burgueño AL; Rey-Funes M; Loidl CF; Mallardi P; Martino JS; Castaño GO; Sookoian S
    Gut; 2013 Sep; 62(9):1356-63. PubMed ID: 22879518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
    Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
    Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.
    Estep M; Armistead D; Hossain N; Elarainy H; Goodman Z; Baranova A; Chandhoke V; Younossi ZM
    Aliment Pharmacol Ther; 2010 Aug; 32(3):487-97. PubMed ID: 20497147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of the non-alcoholic fatty liver disease activity score.
    Hjelkrem M; Stauch C; Shaw J; Harrison SA
    Aliment Pharmacol Ther; 2011 Jul; 34(2):214-8. PubMed ID: 21585409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased expression of Ob-Rb and its relationship with the overexpression of TGF-beta1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis.
    Cayón A; Crespo J; Mayorga M; Guerra A; Pons-Romero F
    Liver Int; 2006 Nov; 26(9):1065-71. PubMed ID: 17032406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of disease progression in nonalcoholic fatty liver disease.
    Jou J; Choi SS; Diehl AM
    Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation and management of obesity-related nonalcoholic fatty liver disease.
    Nugent C; Younossi ZM
    Nat Clin Pract Gastroenterol Hepatol; 2007 Aug; 4(8):432-41. PubMed ID: 17667992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
    Serfaty L; Lemoine M
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
    Park SH
    Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.
    Aubert J; Begriche K; Knockaert L; Robin MA; Fromenty B
    Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):630-7. PubMed ID: 21664213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation of mitochondrial DNA in livers from patients with alcoholic hepatitis and nonalcoholic steatohepatitis.
    Kawahara H; Fukura M; Tsuchishima M; Takase S
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S54-60. PubMed ID: 17331167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathology of nonalcoholic fatty liver disease.
    Yeh MM; Brunt EM
    Am J Clin Pathol; 2007 Nov; 128(5):837-47. PubMed ID: 17951208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.
    Targher G; Chonchol M; Miele L; Zoppini G; Pichiri I; Muggeo M
    Semin Thromb Hemost; 2009 Apr; 35(3):277-87. PubMed ID: 19452403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Imaging of NASH].
    Tanimoto A; Tomita K
    Nihon Rinsho; 2006 Jun; 64(6):1127-32. PubMed ID: 16768120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
    Wieckowska A; McCullough AJ; Feldstein AE
    Hepatology; 2007 Aug; 46(2):582-9. PubMed ID: 17661414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.